Figure 1
From: Hepatitis C-associated hepatocellular carcinomas in non-cirrhotic livers
The combined prevalence (16%) of HCV in the non-cirrhotic livers with hepatocellular carcinoma at two institutes (17% for JHU (Johns Hopkins University) and 14% for UW (University of Washington)) is significantly higher than the prevalence of HCV antibodies in the general US population (1.6%).
